Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals
Status:
Terminated
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The primary aim of this study is to determine the effects of the HIV integrase inhibitor,
raltegravir, in cerebrospinal fluid (CSF). This will be accomplished by collecting CSF before
and after initiation of either raltegravir or another antiretroviral, efavirenz, each in
combination with two other antiretrovirals. Assessments will include HIV RNA levels (viral
load), neuropsychological testing, mood assessments, and quality of life assessments.